The use of PARP-1 inhibitors in combination with standard chemotherapeutic agents also, seems attractive in the sense that sensitizing tumor cells to cytotoxic agents might enable the use of lower doses, while maintaining the same relative efficacy with reduced toxic side effects. The gene discussed is PARP1; the disease is neoplasm.